CMI published a business research report on “Porphyria Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2021–2027”. Porphyria Treatment with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items.
Porphyria Treatment Market report includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Porphyria Treatment Market offers complete, proficient report delivering market research data that is relevant for new market entrants or set up players. Key strategies of the companies operating in the market and their impact analysis have been included in the report.
Request for Analysis of COVID-19 Impact on Porphyria Treatment Market – https://www.coherentmarketinsights.com/insight/request-sample/1706
Porphyria is an inherited rare disorder that affects the nervous system or skin and may cause abdominal pain. Cells of porphyria patients are unable to change body chemicals called porphyrins and its precursors into heme, the substance responsible for blood color. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the exact rates of porphyria are unknown and vary globally. For instance, porphyria cutanea tarda is most common in the U.S., and variegate porphyria is frequent in South America. Some porphyria such as erythropoietic protoporphyria, hepatoerythropoietic porphyria, and congenital erythropoietic porphyria occur when an individual receives two abnormal genes, one from each parent. The chances of an individual passing the abnormal gene or genes to the next generation depends on the type of porphyria. Acute porphyria affects the nervous system and abdomen. It develops in a few hours or days and can last up to several weeks. Cutaneous porphyria affects the skin. According to the American Porphyria Foundation, acute porphyria affects around 1 to 2 individuals per 100,000. High incidence rate was reported in South Africa and Sweden. The foundation promotes comprehensive care that is necessary for treating individuals with porphyria. It promotes disease awareness, reduces stigma associated with porphyria through physician education, and provides support for those affected. The foundation also organized the Porphyria Awareness Week in April 2018, 21-28.
Porphyria Treatment Market Dynamics
The most common tests used for porphyria diagnosis are measurements of substances such as porphyrin precursors and porphyrins, in blood plasma, red blood cells, feces, and urine. Measuring enzymes in cells and mutations in DNA is useful for confirmation and family studies. Though, no cure is available for porphyria, there is treatment for each type of the disease. Treatment depends on the type and severity of the disorder and can involve treating with heme, giving medicines to relieve the symptoms, or drawing blood. Drugs like Thorazine, Chlorpromazine, Panhematin and Hemin can be used to treat symptoms of porphyria. Panhematin (Recordati Rare Diseases) is used for treating acute porphyria. It is a lyophilized form of alkaline heme that has to be reconstructed immediately before administration and should be infused into a large peripheral vein. As per American Porphyria Foundation, Panhematin is the only commercially available heme therapy in the U.S.
Request for Analysis of COVID-19 Impact on Porphyria Treatment Market – https://www.coherentmarketinsights.com/insight/request-pdf/1706
Porphyria Cutanea Tarda (PCT) is the most common and treatable form of porphyria and occurs due to deficiency of the enzyme, uroporphyrinogen decarboxylase (UROD). PCT is a genetic disorder, however, some people have a genetic (autosomal dominant) deficiency of UROD that results in growth of PCT. Most people with the inherited enzyme deficiency remain latent and show no symptoms. Various environmental factors can impact the occurrence and severity of symptoms of porphyria. Smoking, alcohol, change in hormones levels, stress, certain drugs, and dieting or fasting can trigger the signs and symptoms of some forms of porphyria. Moreover, exposure to sunlight severely damages the skin of people with cutaneous porphyria. However, low incidence rates of porphyria can negatively impact the porphyria treatment market
Porphyria treatment Market Regional Insights
Regional segmentation of porphyria treatment market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe are expected to generate significant revenue share in the porphyria treatment market, owing to high presence of major industry players launching new products and conducting R&D for novel product development. For instance, in April 2018, Alnylam Pharmaceuticals, the leading RNAi therapeutics company, presented new results from the Phase 1 and Phase 1/2 open-label extension (OLE) studies of givosiran (RNAi therapeutic) targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria. These results were presented at the European Association for the Study of the Liver (EASL), France. According to American Porphyria Foundation 2017, all forms of porphyria affect less than 200,000 people in the U.S. In Europe, the prevalence of the porphyria cutanea tarda (PCT) is 1 in 10,000, erythropoietic protoporphyria (EPP) is around 1 in 50,000 to 75,000, and acute intermittent porphyria (AlP) is about 1 in 20,000. Congenital erythropoietic porphyria (CEP) is very rare with a prevalence rate of 1 in 1,000,000 or fewer.
Reasons to Purchase this Report
• Current and future of global Porphyria Treatment market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Buy This Full Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1706
Porphyria Treatment Market Competitive Landscape
Key players operating in the porphyria treatment market are ACON Laboratories, Inc., Bio-Rad Laboratories, Inc., Dahaner, Hoffmann-La Roche Ltd, Siemens AG, ARKRAY, Inc., and Sysmex Corporation. Industry players are working towards development of new treatments for the disease.
Porphyria Treatment Market Taxonomy
On the basis of drugs, the porphyria treatment market is segmented into:
On the basis of end-user, the porphyria treatment market is segmented into:
- Research Centers
On the basis of region, the porphyria treatment market is segmented into:
- North America
- Latin America
- Asia Pacific
- Middle East
Main points in Porphyria Treatment Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Porphyria Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Porphyria Treatment Industry Impact
Chapter 2 Global Porphyria Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Porphyria Treatment (Volume and Value) by Type
2.3 Global Porphyria Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Porphyria Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Porphyria Treatment Market Analysis
Chapter 6 East Asia Porphyria Treatment Market Analysis
Chapter 7 Europe Porphyria Treatment Market Analysis
Chapter 8 South Asia Porphyria Treatment Market Analysis
Chapter 9 Southeast Asia Porphyria Treatment Market Analysis
Chapter 10 Middle East Porphyria Treatment Market Analysis
Chapter 11 Africa Porphyria Treatment Market Analysis
Chapter 12 Oceania Porphyria Treatment Market Analysis
Chapter 13 South America Porphyria Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Porphyria Treatment Business
Chapter 15 Global Porphyria Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Major Point Answered in Porphyria Treatment Market Research Study are: –
• What will the market growth rate, Overview and Analysis by Type of Porphyria Treatment market in 2026?
• What are the key factors driving, Analysis by Applications and Countries Porphyria Treatment market?
• What are Dynamics, This Overview Includes Analysis of Scope, and price analysis of top Manufacturers Profiles of Porphyria Treatment market?
• Who are Opportunities, Risk and Driving Force of Porphyria Treatment market? Knows Upstream Raw Materials Sourcing and Downstream Buyers
• Who are the key vendors in Porphyria Treatment market space? Business Overview by Type, Applications, Gross Margin and Market Share
• What are the Porphyria Treatment market opportunities and threats faced by the vendors in the market?
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027